Irinotecán Hospira (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is converted inside cancer cells to SN‑38, which inhibits topoisomerase I. This enzyme normally relaxes DNA during replication; its inhibition leads to DNA strand breaks that cannot be repaired, causing cancer cell death.

The dose of Irinotecán Hospira is individualized by the prescribing oncologist based on factors such as cancer stage, patient weight, liver function, and prior treatments. No fixed regimen is provided here; the prescriber determines the appropriate dosing schedule.

Safety data for Irinotecán Hospira in pregnancy and lactation are limited. It should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus, and breastfeeding is generally not recommended while receiving treatment.

To order Irinotecán Hospira, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Irinotecan is a widely used topoisomerase I inhibitor with a well‑characterized efficacy profile in colorectal cancer. Compared with alternatives such as topotecan, irinotecan generally offers a broader indication range in solid tumors and is often preferred in combination regimens, though toxicity profiles differ and must be considered.

Irinotecán Hospira should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is given by intravenous infusion under controlled clinical conditions. The infusion rate and duration are determined by the treating physician, and patients are monitored closely for any adverse reactions during and after administration.

Serious risks include severe diarrhea that can lead to intestinal perforation, febrile neutropenia, hepatotoxicity, and hypersensitivity reactions such as anaphylaxis. Prompt recognition and management of these events are essential to minimize complications.

Patients with known hypersensitivity to irinotecan or any of its excipients, those with severe uncontrolled infections, or individuals with significant liver dysfunction should avoid using Irinotecán Hospira. The drug is also contraindicated in patients for whom the risks outweigh the potential therapeutic benefits.